Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404380

2023-01-01

Abstract:Pten null T-ALL blasts show lower levels of phospho-AKT in response to JQ1 in comparison to LICs.

What problem does this paper attempt to address?

Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404389

2023-01-01

Abstract:Cellular and biochemical effects of JQ1 in T-ALL.
Supplementary Figure 5 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404383

2023-01-01

Abstract:Primary human pediatric T-ALL samples show elevated levels of phospho-AKT.
Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404395.v1

2023-01-01

Abstract:Testing the efficacy of combination therapy using small molecules to reduce Pten null leukemia burden and LICs in vivo.
Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404386

2023-01-01

Abstract:Sensitivity of primary human pediatric T-ALL cells to rapamycin and JQ1 in vitro.
Supplementary Figure 7 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404377.v1

2023-01-01

Abstract:DN thymocytes (DN3 and DN4) show highest levels of c-Myc in comparison to DP and SP populations.
Supplementary Figure 2 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404392

2023-01-01

Abstract:Cellular effects of rapamycin in T-ALL.
Data from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.c.6506591.v1

2023-01-01

Abstract:AbstractDisease relapse remains the major clinical challenge in treating T-cell acute lymphoblastic leukemia (T-ALL), particularly those with PTEN loss. We hypothesized that leukemia-initiating cells (LIC) are responsible for T-ALL development and treatment relapse. In this study, we used a genetically engineered mouse model of Pten−/− T-ALL with defined blast and LIC-enriched cell populations to demonstrate that LICs are responsible for therapeutic resistance. Unlike acute and chronic myelogenous leukemia, LICs in T-ALL were actively cycling, were distinct biologically, and responded differently to targeted therapies in comparison with their differentiated blast cell progeny. Notably, we found that T-ALL LICs could be eliminated by cotargeting the deregulated pathways driven by PI3K and Myc, which are altered commonly in human T-ALL and are associated with LIC formation. Our findings define critical events that may be targeted to eliminate LICs in T-ALL as a new strategy to treat the most aggressive relapsed forms of this disease. Cancer Res; 74(23); 7048–59. ©2014 AACR.
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404374

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, and Characteristics of primary human pediatric T-ALL samples (Supplementary Table S1).
Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Yuan Kong,Yi-Lin Wu,Yang Song,Min-Min Shi,Xie-Na Cao,Hong-Yan Zhao,Ya-Zhen Qin,Yue-Yun Lai,Hao Jiang,Qian Jiang,Xiao-Jun Huang

DOI: https://doi.org/10.1186/s12967-017-1286-5

IF: 8.44

2017-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that LPCs were enriched in the CD34+CD38-CD58- fraction in human Ph+ALL. Additionally, a cohort study demonstrated that Ph+ALL patients with a LPCs phenotype at diagnosis exhibited a significantly higher cumulative incidence of relapse than those with the other cell phenotypes even with uniform front-line imatinib-based therapy pre- and post-allotransplant, thus highlighting the need for novel LPCs-based therapeutic strategies.METHODS:RNA sequencing (RNA-Seq) and real-time quantitative polymerase chain reaction (qRT-PCR) were performed to analyze the gene expression profiles of the sorted LPCs and other cell fractions from patients with de novo Ph+ALL. In order to assess the effects of the selective BCR-ABL and/or Janus kinase (JAK)2 inhibition therapy by the treatment with single agents or a combination of ruxolitinib and imatinib or nilotinib on Ph+ALL LPCs, drug-induced apoptosis of LPCs was investigated in vitro, as well as in vivo using sublethally irradiated and anti-CD122-conditioned NOD/SCID xenograft mouse assay. Moreover, western blot analyses were performed on the bone marrow cells harvested from the different groups of recipient mice.RESULTS:RNA-Seq and qRT-PCR demonstrated that JAK2 was more highly expressed in the sorted LPCs than in the other cell fractions in de novo Ph+ALL patients. Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.CONCLUSIONS:In summary, this pre-clinical study provides a scientific rationale for simultaneously targeting BCR-ABL and JAK2 activities as a promising anti-LPCs therapeutic approach for patients with de novo Ph+ALL.
Abstract B12: Co-inhibition of PI3K and Myc Pathways is Synthetic Lethal to PTEN Null T-ALL Leukemia-Initiating Cells

Suzanne Schubbert,Anjelica Cardenas,Christopher Wei,Lingda Ma,Consuelo Garcia,Wei Guo,Hong Wu

DOI: https://doi.org/10.1158/1535-7163.pms-b12

2013-01-01

Molecular Cancer Therapeutics

Abstract:Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a common hematological malignancy associated with poor prognosis and significant risk of relapse. Loss of PTEN function due to mutations or deletions is common in primary T-ALL samples and is associated with resistance to therapeutic agents. We previously developed a VEC-Cre+;Ptenloxp/loxp (Pten null) T-ALL model to investigate the molecular and cellular mechanisms underlying T-ALL pathogenesis and resistance to therapy. Pten-null T-ALL develops after acquisition of a T cell receptor α/δ-c-myc translocation that causes c-Myc over-expression, and the leukemia-initiating cells, or leukemia stem cells (LSCs), are enriched in a c-kitmidCD3+ subpopulation. The goal of our current study is to develop improved therapeutic approaches to target LSCs and eliminate T-ALL. We hypothesize that small molecule inhibitors that target molecular lesions and pathways required for the development and survival of Pten null LSCs and T-ALL may be potent in eliminating LSCs and abolishing T-ALL. Rapamycin, an inhibitor of the PI3K downstream kinase mTOR, can suppress leukemia development in Pten null pre-leukemic mice, but is insufficient to eliminate LSCs and T-ALL. Therefore, we are investigating the therapeutic utility of combinational therapies that co-target multiple deregulated pathways that are critical for LSC formation and T-ALL survival. We found that combination treatment of Pten null T-ALL mice with rapamycin and VX-680, an Aurora kinase inhibitor shown to have synthetic lethality with Myc over-expression, causes robust elimination of leukemia blasts and significantly diminishes the LSC population. Functional studies for leukemia-initiating-cell activity using transplantation of treated bone marrow into NOD-SCID-IL2rγ-/-(NSG) recipients showed that dual treatment reduced leukemia-initiating-cell activity in bone marrow by at least 100-fold in comparison to single agent alone. Importantly, a large portion of Pten null T-ALL LSCs are actively cycling (~50% in S-phase), which may contribute to the mechanism underlying the efficacy of VX-680. We have developed a T-ALL in vitro culture system derived from primary Pten null T-ALL mice to conduct more detailed evaluation of the cellular and biochemical effects of rapamycin and VX-680, perform mechanistic analysis, and screen additional cell cycle-directed and Myc-targeted agents. We found that Pten null T-ALL is highly sensitive to killing by the CDK1 inhibitor purvalanol and JQ1, a bromodomain inhibitor reported to down-regulate c-myc expression that is suitable for use in vivo. Rapamycin and JQ1 combination treatment of Pten null T-ALL mice causes a significant reduction in both the leukemia blast and LSC populations, similar to the effects of rapamycin and VX-680 combination therapy. Our results highlight the importance of understanding the mechanisms underlying T-ALL development and survival and show potent synthetic lethality of PI3K and Myc pathway co-inhibition in PTEN null T-ALL LSCs. Importantly, such targeted combination therapy may offer an improved therapeutic approach to treat human T-ALL. Citation Format: Suzanne Schubbert, Anjelica Cardenas, Christopher Wei, Lingda Ma, Consuelo Garcia, Wei Guo, Hong Wu. Co-inhibition of PI3K and Myc pathways is synthetic lethal to PTEN null T-ALL leukemia-initiating cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities; May 17-20, 2013; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(5 Suppl):Abstract nr B12.
Supplemetary Figure S1-S8 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Jingfeng Zhou,Danian Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.22462449.v1

2023-01-01

Abstract:Figure S1 - Biological and pharmacological inhibition of EZH2 potently dampens growth of IM-sensitive and -resistant CML cells; Figure S2 - GSK126 induces apoptosis in CML cells in a dose- and time-dependent manner; Figure S3 - GSK126 elicits cytochrome c release and mitochondrial damage; Figure S4 - Administration of GSK126 in CML mice reduces LSCs in spleen nucleated cells from CML mice; Figure S5 - Knockdown of EZH2 reduces in vivo LSCs in CML mice; Figure S6 - Pharmacological and biological inhibition of EZH2 in CML mice has minimal effect on LSCs and progenitor cells in BM and spleen nucleated cells from CML mice; Figure S7 - BCR-ABL is not involved in the EZH2 knockdown-enabled PTEN transcriptional elevation; Figure S8 - Knockdown of PTEN weakens the effect of LSCs reduction mediated by silencing EZH2.
Suppression of Leukemia Development Caused by Pten Loss

Wei Guo,Suzanne Schubbert,James Y. Chen,Bahram Valamehr,Sherly Mosessian,Hubing Shi,Nhi H. Dang,Consuelo Garcia,Mariana F. Theodoro,Marileila Varella-Garcia,Hong Wu

DOI: https://doi.org/10.1073/pnas.1006937108

2011-01-01

Abstract:Multiple genetic or molecular alterations are known to be associated with cancer stem cell formation and cancer development. Targeting such alterations, therefore, may lead to cancer prevention. By crossing our previously established phosphatase and tensin homolog (Pten) - null acute T-lymphoblastic leukemia (T-ALL) model onto the recombination-activating gene 1 −/− background, we show that the lack of variable, diversity and joining [V(D)J] recombination completely abolishes the Tcrα/δ-c-myc translocation and T-ALL development, regardless of β-catenin activation. We identify mammalian target of rapamycin (mTOR) as a regulator of β-selection. Rapamycin, an mTOR-specific inhibitor, alters nutrient sensing and blocks T-cell differentiation from CD4 − CD8 − to CD4 + CD8 + , the stage where the Tcrα/δ-c-myc translocation occurs. Long-term rapamycin treatment of preleukemic Pten -null mice prevents Tcrα/δ-c-myc translocation and leukemia stem cell (LSC) formation, and it halts T-ALL development. However, rapamycin alone fails to inhibit mTOR signaling in the c-Kit mid CD3 + Lin − population enriched for LSCs and eliminate these cells. Our results support the idea that preventing LSC formation and selectively targeting LSCs are promising approaches for antileukemia therapies.
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

Teresa Palomero,Maria Luisa Sulis,Maria Cortina,Pedro J Real,Kelly Barnes,Maria Ciofani,Esther Caparros,Jean Buteau,Kristy Brown,Sherrie L Perkins,Govind Bhagat,Archana M Agarwal,Giuseppe Basso,Mireia Castillo,Satoru Nagase,Carlos Cordon-Cardo,Ramon Parsons,Juan Carlos Zúñiga-Pflücker,Maria Dominguez,Adolfo A Ferrando

DOI: https://doi.org/10.1038/nm1636

IF: 82.9

2007-09-16

Nature Medicine

Abstract:Gain-of-function mutations in NOTCH1 are common in T-cell lymphoblastic leukemias and lymphomas (T-ALL), making this receptor a promising target for drugs such as γ-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation. However, the enthusiasm for these therapies has been tempered by tumor resistance and the paucity of information on the oncogenic programs regulated by oncogenic NOTCH1. Here we show that NOTCH1 regulates the expression of PTEN (encoding phosphatase and tensin homolog) and the activity of the phosphoinositol-3 kinase (PI3K)-AKT signaling pathway in normal and leukemic T cells. Notch signaling and the PI3K-AKT pathway synergize in vivo in a Drosophila melanogaster model of Notch-induced tumorigenesis, and mutational loss of PTEN is associated with human T-ALL resistance to pharmacological inhibition of NOTCH1. Overall, these findings identify transcriptional control of PTEN and regulation of the PI3K-AKT pathway as key elements of the leukemogenic program activated by NOTCH1 and provide the basis for the design of new therapeutic strategies for T-ALL.

biochemistry & molecular biology,cell biology,medicine, research & experimental
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Christian Hurtz,Katerina Hatzi,Leandro Cerchietti,Melanie Braig,Eugene Park,Yong-mi Kim,Sebastian Herzog,Parham Ramezani-Rad,Hassan Jumaa,Martin C Müller,Wolf-Karsten Hofmann,Andreas Hochhaus,B Hilda Ye,Anupriya Agarwal,Brian J Druker,Neil P Shah,Ari M Melnick,Markus Müschen

DOI: https://doi.org/10.1084/jem.20110304

2011-10-24

Abstract:Chronic myeloid leukemia (CML) is induced by the oncogenic BCR-ABL1 tyrosine kinase and can be effectively treated for many years with tyrosine kinase inhibitors (TKIs). However, unless CML patients receive life-long TKI treatment, leukemia will eventually recur; this is attributed to the failure of TKI treatment to eradicate leukemia-initiating cells (LICs). Recent work demonstrated that FoxO factors are critical for maintenance of CML-initiating cells; however, the mechanism of FoxO-dependent leukemia initiation remained elusive. Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO in self-renewal signaling of CML-initiating cells. BCL6 represses Arf and p53 in CML cells and is required for colony formation and initiation of leukemia. Importantly, peptide inhibition of BCL6 in human CML cells compromises colony formation and leukemia initiation in transplant recipients and selectively eradicates CD34(+) CD38(-) LICs in patient-derived CML samples. These findings suggest that pharmacological inhibition of BCL6 may represent a novel strategy to eradicate LICs in CML. Clinical validation of this concept could limit the duration of TKI treatment in CML patients, which is currently life-long, and substantially decrease the risk of blast crisis transformation.
PD-1 Signalling Defines and Protects Leukaemic Stem Cells from T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukaemia

Xi Xu,Wenwen Zhang,Li Xuan,Yanhui Yu,Wen Zheng,Fang Tao,Jacqelyn Nemechek,Chong He,Weiwei Ma,Xue Han,Siyu Xie,Minyi Zhao,Jian Wang,Yuhua Qu,Qifa Liu,John M. Perry,Linjia Jiang,Meng Zhao

DOI: https://doi.org/10.1038/s41556-022-01050-3

IF: 21.3

2023-01-01

Nature Cell Biology

Abstract:T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy with poor prognosis, but a decisive marker and effective treatment for leukaemia stem cells (LSCs) remain unclear. Here, using lineage tracing, limiting dilution assays and in vivo live imaging approaches, we identify rare inhibitory receptor programmed cell death 1 (PD-1)-expressing cells that reside at the apex of leukaemia hierarchy for initiation and relapse in T-ALL. Ablation of PD-1-expressing cells, deletion of PD-1 in T-ALL cells or blockade of PD-1 or PD-1 ligand 1 significantly eradicated LSCs and suppressed disease progression. Combination therapy using PD-1 blockade and chemotherapy substantially extended the survival of mice engrafted with mouse or human T-ALL cells. Mechanistically, PD-1+ LSCs had high NOTCH1-MYC activity for disease initiation. Furthermore, PD-1 signalling maintained quiescence and protected LSCs against T cell receptor-signal-induced apoptosis. Overall, our data highlight the hierarchy of leukaemia by identifying PD-1(+) LSCs and provide a therapeutic approach for the elimination of LSCs through PD-1 blockade in T-ALL.
Lnk (Sh2b3) Synergizes With Tp53 In Suppressing B-Precursor Acute Lymphoblastic Leukemia Through Il-7 Receptor Signaling

Ying Cheng,Kudakwashe R. Chikwava,Chao Wu,Anchit Bhagat,John K. Choi,Wei Tong

DOI: https://doi.org/10.1182/blood.v124.21.1074.1074

IF: 20.3

2014-01-01

Blood

Abstract:B-precursor acute lymphoblastic leukemia (B-ALL) is the leading cause of cancer-related deaths in children and commonly has a poor outcome in adults. Gene profiling and exome sequencing of high-risk ALLs led to the recent identification of the Philadelphia chromosome (Ph)-like ALL subtype. These leukemias have gene expression profiles similar to BCR-ABL1-positive (Ph+) ALL, but lack a BCR-ABL1 rearrangement, and often result in poor outcomes. Many Ph-like ALL-associated mutations identified to date are known or predicted to activate oncogenic cytokine receptor signaling pathways, particularly those associated with JAK. The lymphocyte adaptor protein LNK (also called SH2B3) has emerged as a powerful negative regulator of cytokine-mediated JAK2 signaling in hematopoietic stem cells (HSCs). Loss-of-function LNK mutations and deletions have recently been described in B-ALL, and germline loss of LNK contributes to pediatric ALL development. However, the mechanisms by which LNK alterations impact leukemogenesis remain poorly understood. Here we show that LNK synergizes with TP53 and INK4a in suppressing B-ALL development in mice. Tp53-/-Lnk-/- mice developed highly aggressive and transplantable B-ALL with 100% penetrance in contrast to T-lymphoma or sarcoma development observed in Tp53-/- mice. Importantly, gene expression profiles of Tp53-/-Lnk-/- B-ALL blasts were similar to those of human Ph-like B-ALLs, validating the relevance of this model for preclinical studies. Tp53-/-Lnk-/- pro-B progenitors initiated B-ALL in the transplanted recipients, and Lnk loss-of-heterozygosity (LOH) was found exclusively in B-ALL cells from Tp53-/-Lnk+/- mice, but not in HSCs, common lymphoid progenitors, or cells of myeloid/T cell lineages, attesting that LNK is a bona fide tumor suppressor in the committed B-cell precursors. Mechanistically, we found that pre-leukemic Lnk-/-Tp53-/- pro-B progenitors were hypersensitive to IL-7 and showed markedly enhanced self-renewal ability in vitro and in vivo. Our genetic studies revealed that LNK controls normal B cell and B-ALL development independently of its effects on HSCs and specifically regulates pro-B cell homeostasis. A novel phosphoflow cytometry approach in freshly isolated BM cells that combines the surface marker B220, intracellular mu-heavy chain detection, and phospho-specific antibodies enabled separation of subpopulations of B progenitors with distinct IL-7 responsiveness. Using this approach, we demonstrated that LNK deficiency potentiated STAT5 activation in response to IL-7 in pre-leukemic pro-B cells. Of note, Lnk-/-p53-/- leukemic blasts with elevated pSTAT5, were less sensitive to JAK inhibitors than pre-leukemic B progenitors, in part due to constitutive activation of MAPK and AKT/mTOR pathways. Our results invoke the targeting of these pathways as novel therapeutic approaches in B-ALL. In sum, we have developed a novel B-ALL mouse model suitable for preclinical studies aimed at further deciphering the pathogenic mechanisms underlying this disease and exploring new therapeutic strategies.
PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Jingfeng Zhou,Danian Nie,Juan Li,Xin Du,Yuhong Lu,Yangqiu Li,Chang Liu,Wei Dai,Yun Wang,Yanli Jin,Jingxuan Pan

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1533

IF: 13.801

2018-01-01

Clinical Cancer Research

Abstract:Purpose: Leukemia stem cells (LSCs) are an important source of tyrosine kinase inhibitor resistance and disease relapse in patients with chronic myelogenous leukemia (CML). Targeting LSCs may be an attractive strategy to override this thorny problem. Given that EZH2 was overexpressed in primary CML CD34 thorn cells, our purpose in this study was to evaluate the effects of targeting EZH2 on CML LSCs and clarify its underlying mechanism. Experimental Design: Human primary CML CD34 thorn cells and retrovirally BCR-ABL-driven CML mouse models were employed to evaluate the effects of suppression of EZH2 by GSK126-or EZH2-specific shRNA in vitro and in vivo. Recruitment of EZH2 and H3K27me3 on the promoter of tumorsuppressor gene PTEN in CML cells wasmeasured by chromatin immunoprecipitation assay. Results: Our results showed that pharmacologic inhibition of EZH2 by GSK126 not only elicited apoptosis and restricted cell growth in CML bulk leukemia cells, but also decreased LSCs in CML CD34 thorn cells while sparing those from normal bone marrow CD34 thorn cells. Suppression of EZH2 by GSK126 or specific shRNA prolonged survival of CML mice and reduced the number of LSCs in mice. EZH2 knockdown resulted in elevation of PTEN and led to impaired recruitment of EZH2 and H3K27me3 on the promoter of PTEN gene. The effect of EZH2 knockdown in the CML mice was at least partially reversed by PTEN knockdown. Conclusions: These findings improve the understanding of the epigenetic regulation of stemness in CML LSCs and warrant clinical trial of GSK126 in refractory patients with CML. Clin Cancer (C) 2017 AACR.
Pten Is A Tumor Suppressor In Cml Stem Cells And Bcr-Abl-Induced Leukemias In Mice

Cong Peng,Yaoyu Chen,Zhongfa Yang,Haojian Zhang,Lori Osterby,Alan G Rosmarin,Shaoguang Li

DOI: https://doi.org/10.1182/blood-2009-06-228130

IF: 20.3

2010-01-01

Blood

Abstract:The tumor suppressor gene phosphatase and tensin homolog (PTEN) is inactivated in many human cancers. However, it is unknown whether PTEN functions as a tumor suppressor in human Philadelphia chromosome-positive leukemia that includes chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL) and is induced by the BCR-ABL oncogene. By using our mouse model of BCR-ABL-induced leukemias, we show that Pten is down-regulated by BCR-ABL in leukemia stem cells in CML and that PTEN deletion causes acceleration of CML development. In addition, overexpression of PTEN delays the development of CML and B-ALL and prolongs survival of leukemia mice. PTEN suppresses leukemia stem cells and induces cell-cycle arrest of leukemia cells. Moreover, PTEN suppresses B-ALL development through regulating its downstream gene Akt1. These results demonstrate a critical role of PTEN in BCR-ABL-induced leukemias and suggest a potential strategy for the treatment of Philadelphia chromosome positive leukemia. (Blood. 2010; 115: 626-635)

Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 5 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 7 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 2 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Data from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Abstract B12: Co-inhibition of PI3K and Myc Pathways is Synthetic Lethal to PTEN Null T-ALL Leukemia-Initiating Cells

Supplemetary Figure S1-S8 from PTEN is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia

Suppression of Leukemia Development Caused by Pten Loss

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

PD-1 Signalling Defines and Protects Leukaemic Stem Cells from T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukaemia

Lnk (Sh2b3) Synergizes With Tp53 In Suppressing B-Precursor Acute Lymphoblastic Leukemia Through Il-7 Receptor Signaling

PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Pten Is A Tumor Suppressor In Cml Stem Cells And Bcr-Abl-Induced Leukemias In Mice